 iStockAnalyst | Regeneron Acquires Full Rights to Two Novel Ophthalmology Development ... PipelineReview.com (press release) TARRYTOWN, NY, USA I May 3, 2013 I Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has expanded its ophthalmology portfolio by acquiring full exclusive rights to two families of novel antibodies invented at Regeneron and ... Sanofi lets go of rights to Regeneron's antibodies in ophthalmology Regeneron Gains Full Rights to Ophthalmology Antibodies from Sanofi Regeneron Q1 Profit Up, Beats Estimates; Ups Eylea Sales Forecast - Quick Facts |
